Trial Profile
A pilot retrospective study of efficacy and safety of baricitinib in treating refractory intestinal Behcet's disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jul 2023
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary)
- Indications Behcet's syndrome
- Focus Adverse reactions; Therapeutic Use
- 03 Jun 2023 Results (n=17) assessing efficacy and safety of the JAK1/JAK2 inhibitor baricitinib in BD patients with refractory vascular involvement presented at the 24th Annual Congress of the European League Against Rheumatism
- 28 Feb 2023 New trial record
- 01 Feb 2023 Results published in the Clinical Immunology